cancer - 2/127 - Xconomy

Entry	Author	Date	Location
J&J Prostate Cancer Drug Hits Goal; Hurts Dendreon, Helps Medivation	Luke Timmerman	03/08/12	New York
San Diego Life Sciences Roundup: Aragon, Illumina, CareFusion, & More	Bruce V. Bigelow	03/08/12	San Diego
The Thinking Behind Domain’s $760M Life Sciences Deal in Russia	Bruce V. Bigelow	03/07/12	San Diego
Oncothyreon Shares Tumble on Lung Cancer Study Speculation	Luke Timmerman	03/06/12	Seattle
San Diego’s Aragon Raises $42 Million, Targets Hormone-Driven Cancers	Bruce V. Bigelow	03/06/12	San Diego
Connect Bestows ‘Hall of Fame’ Award on Hybritech Founder Ted Greene	Bruce V. Bigelow	03/05/12	San Diego
Five Reasons Illumina Should Fight Roche’s Insulting Low-Ball Bid	Luke Timmerman	03/05/12	National
CytomX Therapeutics Seeks to One-Up Lilly, Amgen Cancer Drugs	Luke Timmerman	03/02/12	San Francisco
Xconomist of the Week: Roger Perlmutter’s Parting Thoughts on Amgen	Luke Timmerman	03/01/12	National
Dendreon Adds ImClone Vets to New Management Team	Luke Timmerman	02/28/12	Seattle
Dendreon Stock Tumbles As Company Projects ‘Moderate’ Sales Growth	Luke Timmerman	02/27/12	Seattle
Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris	Luke Timmerman	02/23/12	Seattle
Cell Therapeutics Stock Rises on EU Recommendation for Lymphoma Drug	Luke Timmerman	02/17/12	Seattle
SD Life Sciences Roundup: Celladon, Gen-Probe, Organovo, and More	Bruce V. Bigelow	02/16/12	National
Xconomist of the Week: Peter Kuhn on Detecting Circulating Tumor Cells	Bruce V. Bigelow	02/16/12	San Diego
FDA Approves New Gen-Probe Test for Men at Risk of Prostate Cancer	Bruce V. Bigelow	02/15/12	San Diego
Organovo Raises $6.5M, Lists on OTC, in Alternative Public Offering	Bruce V. Bigelow	02/14/12	San Diego
SD Life Sciences Roundup: Illumina, Applied Proteomics, & Tocagen	Bruce V. Bigelow	02/10/12	San Diego
OncoSec Medical Advancing Inovio’s Technology Against Cancer	Bruce V. Bigelow	02/08/12	San Diego
Applied Proteomics, Co-Founded by Danny Hillis, Gets New CEO, $22.5M	Bruce V. Bigelow	02/07/12	San Diego
Dendreon Names John Johnson CEO After Volatile Year	Arlene Weintraub	02/01/12	Seattle
Cell Therapeutics Pulls FDA Application, Saying It Isn’t Ready For Panel	Luke Timmerman	01/30/12	Seattle
Infinity Drug Fails in Pancreatic Cancer Trial, Shares Fall	Luke Timmerman	01/27/12	Boston
OncoGenex Stays in Prostate Cancer Fray, After J&J, Medivation	Luke Timmerman	01/27/12	Seattle
Millennium, Vertex, Avila, & More Boston Life Sciences Newsmakers	Erin Kutz	01/27/12	Boston
Verastem Bucks the Trend, Raises $55M in IPO	Luke Timmerman	01/26/12	Boston
San Diego Life Sciences Roundup: Illumina, Sequenom, Acutus, & More	Bruce V. Bigelow	01/26/12	San Diego
Millennium Wins FDA OK for New Velcade, Looks to Fend Off Onyx	Luke Timmerman	01/23/12	Boston
Biotech Is Raising More Cash, But Don’t Be Fooled: Startups are Hurting	Luke Timmerman	01/23/12	National
Infinity Offers Hint Of Effect With Pancreatic Cancer Drug	Luke Timmerman	01/20/12	Boston
Page 2 of 43	« previous page · next page »

Entry

Author

Date

Location

J&J Prostate Cancer Drug Hits Goal; Hurts Dendreon, Helps Medivation

Luke Timmerman

03/08/12

New York

San Diego Life Sciences Roundup: Aragon, Illumina, CareFusion, & More

Bruce V. Bigelow

03/08/12

San Diego